Premium
Intraprostatic botulinum toxin type “A” injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double‐blind, controlled trial using urodynamic evaluation
Author(s) -
Totaro Angelo,
Pinto Francesco,
Pugliese Dario,
Vittori Matteo,
Racioppi Marco,
Foschi Nazario,
Bassi Pier Francesco,
Sacco Emilio
Publication year - 2018
Publication title -
neurourology and urodynamics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 90
eISSN - 1520-6777
pISSN - 0733-2467
DOI - 10.1002/nau.23390
Subject(s) - medicine , lower urinary tract symptoms , international prostate symptom score , urology , bladder outlet obstruction , hyperplasia , randomized controlled trial , placebo , prostate , quality of life (healthcare) , overactive bladder , clinical endpoint , alternative medicine , nursing , pathology , cancer
Aims The injection of botulinum neurotoxin A (BTA) into the prostate represents a minimally invasive treatment in patients with lower urinary tract symptoms (LUTS) associated to benign prostatic hyperplasia (BPH). We evaluated the effectiveness of BTA in treating patients with BPH unresponsive to combined medical therapy (CMT), using urodynamic investigations. Methods This is a randomized, placebo‐controlled, double blind trial. Twenty consecutive patients were randomly assigned to receive intraprostatic BTA injection ( n = 10) or saline solution (SS) ( n = 10). Patients in the intervention group (IG) received 200‐300 UI of BTA diluted in 6‐8 mL of SS and injected into the transitional zone. Patients in the control group (CG) were treated with SS alone. Primary endpoint was International Prostate Symptom Score (IPSS). Secondary endpoints were: maximum flow rate (Qmax), postvoid residual volume (PVR), maximum cystometric capacity (MCC), bladder outlet obstruction index (BOOI), safety, quality of life (QoL) score, and Patient Reported Outcome (PROs). Results All patients in the IG reported subjective improvement starting after 1 month. At 3 months of follow‐up IPSS, QoL, PVR were reduced by 55,3% ( P < 0.01), and 50% ( P < 0.01), 80,6%, ( P < 0.01), respectively. Qmax was increased by 68% ( P < 0.01). MCC increased by 27% ( P < 0.01) and BOOI decreased by 54% ( P < 0.01). PROs analysis revealed that 90% of patients in the IG reported a subjective symptomatic relief and treatment satisfaction. No local or systemic side effects were observed in any group. Conclusions These results indicated that intraprostatic BTA is safe and can improve LUTS and QoL in patients with BPH and unsatisfactory response to CMT.